Merck & Co., Inc. (6MK)
Summary
6MK Chart
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions
Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. Company's oncology pipeline advances with FDA acceptance of four regulatory filings, including ifinatamab deruxtecan, and strategic acquisitions like Terns to counter KEYTRUDA's 2028 patent expiry. LIPFENDRA targets statin-treated patients needing further LDL-C reduction, with peak sales potential estimated at $5 billion by 2034, strengthening MRK's cardiometabolic portfolio.
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.
Merck & Co., Inc. (6MK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Merck & Co., Inc. ever had a stock split?
Merck & Co., Inc. Profile
| Diversified Consumer Services Industry | Consumer Discretionary Sector | Robert Davis CEO | XMUN Exchange | 58933Y105 CUSIP |
| US Country | 75,000 Employees | 15 Jun 2026 Last Dividend | 3 Jun 2021 Last Split | 13 Jan 1978 IPO Date |
Overview
Merck & Co., Inc. is a global healthcare leader focused on innovating new solutions to tackle some of the most serious health challenges. Founded in 1891 and headquartered in Rahway, New Jersey, the company operates worldwide, engaging in the discovery, development, manufacturing, and marketing of pharmaceuticals and animal health products. It operates two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment is dedicated to developing and offering human health pharmaceutical products across a range of areas including oncology, cardiovascular, and diabetes, among others. The Animal Health segment works on veterinary pharmaceuticals, vaccines, and health management solutions and services. Merck serves a diverse clientele, including drug wholesalers, retailers, hospitals, government agencies, physicians, veterinarians, and pet owners. Notably, the company invests in several strategic collaborations and agreements with other pharmaceutical giants like AstraZeneca PLC and Bayer AG, aiming to enhance its product offerings and harness innovative treatments for multiple diseases.
Products and Services
The products and services offered by Merck & Co., Inc. span a broad spectrum of medical needs in both human and animal health sectors:
- Keytruda: A forefront immunotherapy for treating various types of cancer.
- Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia: A portfolio of pharmaceuticals addressing hospital acute care, neuroscience, virology, cardiovascular, and diabetes.
- Vaccine Products: Including preventive pediatric, adolescent, and adult vaccines with prominent products like Gardasil/Gardasil 9 for HPV, ProQuad, M-M-R II, and Varivax for measles, mumps, rubella, and chickenpox, RotaTeq for rotavirus, Vaxneuvance for pneumococcal infections, Pneumovax 23 for pneumonia, and Vaqta for hepatitis A.
- Animal Health Solutions: Veterinary pharmaceuticals, vaccines, health management solutions and services, along with digitally connected identification, traceability, and monitoring products aimed at veterinarians, distributors, animal producers, farmers, and pet owners.
In the arena of collaborative efforts, Merck has entered into multiple significant agreements to bolster its product pipeline:
- Daiichi Sankyo's deruxtecan ADC candidates: A development and commercialization agreement covering patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for treating multiple solid tumors.
- AstraZeneca's Lynparza and Koselugo: Co-development and co-commercialization for multiple cancer types, enhancing Merck's portfolio in oncology.
- Collaborations across the industry: Partnerships with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well as Moderna, Inc., aiming to explore and bring new treatments and vaccines to market.
